Tzemach D - Search Results

1

Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.

Gabizon A, Amitay Y, Tzemach D, Gorin J, Shmeeda H, Zalipsky S. Gabizon A, et al. Among authors: tzemach d. J Control Release. 2012 Jun 10;160(2):245-53. doi: 10.1016/j.jconrel.2011.11.019. Epub 2011 Nov 26. J Control Release. 2012. PMID: 22134116

2

Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids.

Avnir Y, Turjeman K, Tulchinsky D, Sigal A, Kizelsztein P, Tzemach D, Gabizon A, Barenholz Y. Avnir Y, et al. Among authors: tzemach d. PLoS One. 2011;6(10):e25721. doi: 10.1371/journal.pone.0025721. Epub 2011 Oct 6. PLoS One. 2011. PMID: 21998684 Free PMC article.

3

Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer.

Shmeeda H, Amitay Y, Gorin J, Tzemach D, Mak L, Stern ST, Barenholz Y, Gabizon A. Shmeeda H, et al. Among authors: tzemach d. J Drug Target. 2016 Nov;24(9):878-889. doi: 10.1080/1061186X.2016.1191081. Epub 2016 Jun 6. J Drug Target. 2016. PMID: 27187807

4

Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues.

Amitay Y, Shmeeda H, Patil Y, Gorin J, Tzemach D, Mak L, Ohana P, Gabizon A. Amitay Y, et al. Among authors: tzemach d. Pharm Res. 2016 Mar;33(3):686-700. doi: 10.1007/s11095-015-1819-7. Epub 2015 Nov 16. Pharm Res. 2016. PMID: 26572644

5

Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.

Shmeeda H, Amitay Y, Tzemach D, Gorin J, Gabizon A. Shmeeda H, et al. Among authors: tzemach d. J Control Release. 2013 May 10;167(3):265-75. doi: 10.1016/j.jconrel.2013.02.003. Epub 2013 Feb 16. J Control Release. 2013. PMID: 23419948

6

Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.

Shmeeda H, Amitay Y, Gorin J, Tzemach D, Mak L, Ogorka J, Kumar S, Zhang JA, Gabizon A. Shmeeda H, et al. Among authors: tzemach d. J Control Release. 2010 Aug 17;146(1):76-83. doi: 10.1016/j.jconrel.2010.04.028. Epub 2010 May 10. J Control Release. 2010. PMID: 20462513

7

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.

Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S. Gabizon A, et al. Among authors: tzemach d. Cancer Chemother Pharmacol. 2010 May;66(1):43-52. doi: 10.1007/s00280-009-1132-4. Epub 2009 Sep 25. Cancer Chemother Pharmacol. 2010. PMID: 19779718

8

Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.

Shmeeda H, Tzemach D, Mak L, Gabizon A. Shmeeda H, et al. Among authors: tzemach d. J Control Release. 2009 Jun 5;136(2):155-60. doi: 10.1016/j.jconrel.2009.02.002. Epub 2009 Feb 7. J Control Release. 2009. PMID: 19331844

9

An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.

Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H, Sapir R. Gabizon A, et al. Among authors: tzemach d. Cancer Chemother Pharmacol. 2008 Apr;61(4):695-702. doi: 10.1007/s00280-007-0525-5. Epub 2007 Jun 5. Cancer Chemother Pharmacol. 2008. PMID: 17549475 Clinical Trial.

10

In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.

Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. Gabizon A, et al. Among authors: tzemach d. Clin Cancer Res. 2003 Dec 15;9(17):6551-9. Clin Cancer Res. 2003. PMID: 14695160

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results